Immunodiagnosis is the use of immune-system molecules, primarily antibodies, to detect the presence of a disease marker in a patient sample. The idea is straightforward: antibodies bind their targets with remarkable specificity, so if you design a test around that binding event, you can identify infections, autoimmune conditions, cancers, and allergies with precision that purely chemical assays struggle to match. From the home pregnancy test to the COVID rapid test to the pathology stains that help surgeons decide how aggressively to treat a tumor, immunodiagnostic methods now underpin a huge share of modern laboratory medicine. The technology traces back to the late 1950s, when the first radioimmunoassay for insulin proved that antibody-based detection could measure substances in blood that were otherwise virtually invisible, but the field has since expanded into dozens of formats suited to different clinical questions.
How Antibody-Based Detection Works
Every immunodiagnostic test exploits the same biological fact: an antibody locks onto a specific molecular shape on its target, called an antigen, the way a key fits a lock. The test designer attaches a signal-generating label to one side of that interaction so the binding event becomes visible. In older tests the label was a radioactive atom; today it is usually an enzyme that produces a color change, a fluorescent molecule, or a gold nanoparticle that turns a line pink. The specificity of the antibody determines what the test detects, while the sensitivity of the signal system determines how little of the target the test can find. Almost every difference between immunodiagnostic platforms comes down to how these two halves are engineered.
ELISA and Its Variants
The enzyme-linked immunosorbent assay, or ELISA, remains the workhorse of clinical immunodiagnosis. In a standard ELISA, a sample is added to a plastic plate coated with a capture molecule, and after a series of wash-and-bind steps, an enzyme-linked antibody generates a measurable color change proportional to the amount of target present. The technique comes in several configurations: direct, indirect, sandwich, and competitive, each varying in how many antibody layers are used and whether the test looks for an antigen or an antibody in the patient’s sample.1PubMed. Enzyme-Linked Immunosorbent Assay: Types and Applications Sandwich ELISA, which traps the target between two antibodies, tends to offer the best combination of sensitivity and specificity for measuring proteins in blood.
ELISA is quantitative and well suited to batch processing, which is why central laboratories use it to screen donated blood for HIV, hepatitis, and other infections. Its main limitation is turnaround time. The multiple incubation and washing steps typically push results to several hours or the next day, which is fine for routine screening but too slow when a doctor needs an answer at the bedside.
Rapid Tests and Lateral Flow Strips
Lateral flow assays solve the speed problem by moving the immunodiagnostic reaction onto a paper-like membrane strip. The sample wicks along the strip, picking up labeled detector particles on the way and delivering them to a test line where capture molecules are immobilized. If the target is present, a colored line appears, often within 15 minutes and with no equipment at all. This is the format behind home pregnancy tests, rapid strep tests, and the COVID antigen tests that became a household item during the pandemic.
During the SARS-CoV-2 response, researchers refined lateral flow designs considerably. One approach used gold-conjugated nanobodies as detector probes on the conjugate pad, with a capture probe on the test line that formed a signal-enhanced immune complex when the virus’s spike protein was present in saliva.2Scientific Reports. Gold conjugated nanobodies in a signal-enhanced lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples Another design captured IgM antibodies against the virus using colloidal gold nanoparticles, producing a visible reddish-purple line at the test zone when the patient’s serum contained those antibodies.3PubMed Central. Rapid Detection of IgM Antibodies against the SARS-CoV-2 Virus via Colloidal Gold Nanoparticle-Based Lateral-Flow Assay The trade-off is sensitivity: lateral flow tests are less sensitive than ELISA, meaning they can miss infections at low viral loads. They excel as screening tools in high-volume or resource-limited settings rather than as confirmatory diagnostics.
Reading the Immune Clock in Infections
When the body fights an infection, it produces different classes of antibodies on different timelines. IgM antibodies appear first, usually rising within the first two weeks, then declining. IgG antibodies follow and persist much longer, sometimes for years. Immunodiagnostic serology takes advantage of this pattern. A positive IgM result suggests a recent or active infection, while an isolated IgG result points to a past infection or vaccination.
The timing is not as tidy as the textbook version implies. In a study tracking SARS-CoV-2 patients, the median IgM titer peaked around day 18 after symptom onset and then dropped, while IgG stabilized above the detection threshold by roughly day 13. Interestingly, in the majority of patients the IgG seroconversion actually happened before IgM, flipping the expected order.4Scientific Reports. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan Both IgM and IgG antibodies were still detectable six months after infection, though their levels declined steeply over that period.5PubMed Central. The Trend of IgG and IgM Antibodies During 6-Month Period After the Disease Episode in COVID-19 Patients Clinicians interpreting serology results need to know roughly when a patient became ill, because the same antibody levels can mean very different things at week one versus week six.
Autoimmune Disease Diagnostics
Immunodiagnosis is equally central to autoimmune medicine. The hallmark screening test for conditions like lupus, Sjögren’s syndrome, and scleroderma is the antinuclear antibody (ANA) test, which checks whether a patient’s blood contains antibodies that attack the body’s own cell nuclei. The traditional method, indirect immunofluorescence on cultured epithelial cells, is considered the reference standard because of its high sensitivity, but it is time-consuming and depends heavily on the skill of the person reading the fluorescence patterns under a microscope.6PubMed Central. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
Solid-phase alternatives, like ANA-ELISA, are faster and more objective. In at least one clinical comparison, ANA-ELISA actually showed better sensitivity and slightly better specificity than immunofluorescence for screening connective tissue diseases, with sensitivity for lupus reaching about 77% compared to roughly 64% for immunofluorescence.7Scientific Reports. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases The debate over which method should be used first remains active, with guidelines still favoring immunofluorescence as the initial screen in many regions. Pattern recognition matters here: certain fluorescence patterns point strongly toward particular autoimmune diseases, and mixed patterns can signal overlapping conditions.8PubMed Central. Analysis of antinuclear antibody titers and patterns by using HEp-2 and primate liver tissue substrate indirect immunofluorescence assay in patients with systemic autoimmune rheumatic diseases
Allergy Testing and IgE
Allergy diagnostics rely on measuring a different antibody class altogether: IgE. When someone is allergic to a substance, their immune system produces IgE antibodies specific to that allergen. A skin prick test delivers a tiny amount of allergen into the skin and watches for a wheal-and-flare reaction, while blood-based tests measure circulating allergen-specific IgE in the lab. The World Allergy Organization notes that skin prick tests tend to be more sensitive, while serum IgE testing is more quantitative and easier to standardize.9World Allergy Organization Journal. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper A newer functional test, the basophil activation test, measures whether a patient’s immune cells actually respond to an allergen in the tube, which can help resolve ambiguous cases, though the test remains too complex for routine use.
Cancer and Tissue Pathology
Immunodiagnosis plays two distinct roles in oncology. The first is immunohistochemistry, or IHC, applied to tissue biopsies. When a pathologist receives a tumor sample, antibody-based stains help determine what kind of cell the cancer came from. The initial step typically uses markers like cytokeratins for epithelial tumors, vimentin for mesenchymal tumors, and CD45 for blood-cell cancers.10PubMed Central. Useful Immunohistochemical Markers of Tumor Differentiation From there, more specific stains narrow the diagnosis further. Newer multiplex IHC techniques can detect two markers simultaneously on the same tissue slide, and some assays now identify specific mutations at the protein level, reducing the need for separate molecular genetic tests.11PubMed. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
The second role is the detection of tumor-associated antigens and autoantibodies in blood, with the aim of catching cancer early. A four-biomarker panel combining three tumor markers with an autoantibody against NY-ESO-1 distinguished lung cancer cases from controls with about 77% sensitivity and 80% specificity in an independent validation set.12PubMed Central. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer That kind of performance is still not reliable enough for population-wide screening on its own, but panels like this could eventually complement imaging as a way to prioritize who gets a CT scan.
When Results Mislead
Immunodiagnostic tests are only as reliable as the antibody interactions they measure, and several biological artifacts can throw results off. The most notorious culprits are heterophilic antibodies, naturally occurring antibodies in a patient’s blood that can cross-react with the animal-derived reagent antibodies in a test kit. When this happens in a sandwich-format assay, the heterophilic antibody can bridge the capture and detector antibodies without any real target being present, generating a falsely elevated result.13PubMed Central. Interferences in immunoassay People who have been exposed to animals or who have received certain mouse-derived therapeutic antibodies are at higher risk for this kind of interference.
Another well-known pitfall is the high-dose hook effect, where an extremely high concentration of the target molecule paradoxically saturates both the capture and detection antibodies separately, preventing sandwich formation and producing a falsely low or even negative result.14PubMed. The investigation of interferences in immunoassay This can be dangerous when measuring something like a tumor marker: the very patients with the most advanced disease may get misleadingly low readings. Labs guard against these problems by running serial dilutions, using blocking agents in reagent formulations, and flagging results that do not fit the clinical picture.
Pushing Sensitivity With Immuno-PCR and Biosensors
Standard ELISA can typically detect targets in the low picogram-per-milliliter range, but some biomarkers are present at concentrations far below that threshold, especially in early disease. Immuno-PCR bridges this gap by replacing the enzyme label in an immunoassay with a short strand of DNA, then amplifying that DNA using polymerase chain reaction. The result is a detection technique that reaches femtogram-level sensitivity, orders of magnitude below conventional ELISA, and applicable to viral, bacterial, parasitic, and fungal targets.15PubMed. Immuno-PCR: Advancements, and applications for infectious diseases diagnosis Immuno-PCR has been validated in clinical settings for measuring biomarkers that are inherently unstable or present in very low concentrations, including cytokines in human serum and aqueous humor samples from the eye.16PubMed. Bringing an immuno-PCR-based pharmacodynamic biomarker assay for reduced human IL-33 in serum, plasma, and aqueous humor into the clinic
Surface plasmon resonance (SPR) biosensors represent another approach to ultrasensitive immunodetection. An SPR sensor measures tiny changes in the way light reflects off a thin metal film when molecules bind to its surface. By functionalizing the surface with antibodies and adding gold-coated magnetic nanoparticles as signal amplifiers, researchers have pushed detection limits for protein biomarkers down to the low femtomolar range.17PubMed Central. Surface Plasmon Resonance Immunosensor with Antibody-Functionalized Magnetoplasmonic Nanoparticles for Ultrasensitive Quantification of the CD5 Biomarker SPR-based designs have also been proposed for rapid virus detection, using multilayered sensor chips with immobilized antibodies against SARS-CoV-2 spike proteins.18PubMed Central. Nano-layered surface plasmon resonance-based highly sensitive biosensor for virus detection: A theoretical approach to detect SARS-CoV-2 These biosensor platforms are still largely in the research stage for clinical diagnostics, but they point toward a future where sensitivity stops being a limiting factor.
Multiplexing and Miniaturization
A recurring frustration with traditional immunodiagnostics is that each test measures one thing at a time. Multiplexed bead-based assays address this by coupling different capture antibodies to microscopically distinct colored beads, then reading the beads with a laser that identifies both the color (which target) and the fluorescent intensity (how much). A single well of a bead-based assay can simultaneously quantify antibodies against 17 or more targets with coefficients of variation in the single digits.19PubMed Central. Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins In veterinary medicine, a similar bead-based platform was used to test cattle fecal samples for three enteric viruses at once, replacing three separate assays with one.20PubMed Central. Development of a multiplexed Luminex assay for simultaneous detection of enteric viruses in cattle Multiplexing matters most when sample volume is limited (a few drops from a finger prick or from a neonate) or when a clinician needs a diagnostic panel rather than a single analyte.
Microfluidic chips shrink the entire immunoassay onto a device the size of a credit card. By running samples through tiny channels etched in plastic or glass, these chips use less reagent, finish faster, and can integrate sample preparation, mixing, and detection into one sealed unit.21PubMed. Materials for Microfluidic Immunoassays: A Review The concept of a true “lab on a chip” that a clinic worker in a remote area could use without training or infrastructure has driven enormous research investment.22PubMed Central. Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges Practical barriers remain, including the difficulty of manufacturing reliable microfluidic devices at scale and keeping reagents stable without refrigeration, but several commercial platforms have already reached clinics.
Smartphones, AI, and Test Interpretation
A lateral flow test produces a line that is either visible or not, and human eyes are mediocre judges of faint lines. Smartphone-based readout systems photograph the test strip, analyze pixel intensity, and return a quantitative result. One system demonstrated that smartphone analysis of SARS-CoV-2 antibody lateral flow kits could quantify IgG levels without any special equipment, enabling point-of-care assessment of humoral immunity in a wide range of settings.23PubMed. The utility of smartphone-based quantitative analysis of SARS-CoV-2-specific antibody lateral flow assays Another group built an app that automatically analyzed up to eight lateral flow tests running in parallel, detecting early failures and outperforming conventional human readout.24PubMed Central. Real-time, smartphone-based processing of lateral flow assays for early failure detection and rapid testing workflows
Artificial intelligence is also entering the laboratory itself. Deep learning models trained on immunofluorescence images of ANA tests achieved an overall accuracy above 92% for classifying staining patterns, a task that traditionally requires trained technologists and remains one of the more subjective steps in autoimmune diagnostics.25EULAR Rheumatology Open. Artificial intelligence for automated classification of antinuclear-antibody indirect immunofluorescence patterns If these tools prove reliable across diverse patient populations and kit manufacturers, they could reduce inter-laboratory variability and free pathologists to focus on genuinely ambiguous cases.
Standardization Across Labs
One of the less visible but deeply consequential problems in immunodiagnosis is that the same sample can produce different numbers when tested in different laboratories using different kits. This became painfully apparent during the pandemic, when dozens of SARS-CoV-2 antibody tests hit the market simultaneously, each calibrated differently. The World Health Organization responded by establishing an International Standard for anti-SARS-CoV-2 immunoglobulin, allowing labs to report results in a common unit (Binding Antibody Units) regardless of the assay they use.26PubMed Central. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays The broader principle applies across immunodiagnosis: without shared reference materials, comparing results between hospitals or clinical trials is guesswork.
Saliva, Aptamers, and Other Departures From Convention
Most immunodiagnostic tests require a blood draw, which limits where and how often testing can happen. Saliva is an appealing alternative because collecting it is painless and can be done without trained staff. Salivary concentrations of several immune and metabolic markers correlate with their serum levels, and researchers have explored saliva-based immunodiagnosis for inflammatory and metabolic conditions, with a particular eye toward pediatric populations where repeated blood draws are difficult.27PubMed Central. Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance The COVID lateral flow test that used saliva samples described earlier in this article is one example of this shift already reaching patients.
On the reagent side, aptamers are emerging as a potential alternative to antibodies themselves. These short nucleic acid sequences are selected in the lab to bind specific targets with high affinity, much like antibodies, but they are cheaper to produce, more stable, easier to modify chemically, and do not require animals to generate. When used in place of antibodies in an ELISA-like format, the resulting assay is sometimes called an enzyme-linked apta-sorbent assay.28PubMed. Aptamers as a replacement for antibodies in enzyme-linked immunosorbent assay Aptamers have not yet displaced antibodies in mainstream clinical testing, but their advantages in manufacturing and shelf life make them especially interesting for diagnostics designed for tropical or resource-limited environments where cold-chain storage is unreliable.
Where It All Started
The field’s origin story is worth knowing because it explains why immunodiagnosis expanded so quickly. In the late 1950s, Solomon Berson and Rosalyn Yalow developed the radioimmunoassay for insulin, proving that an antibody-based method could measure a hormone in blood at concentrations that were previously undetectable.29PubMed. Radioimmunoassay: review of basic principles Yalow received the Nobel Prize in 1977 for the work. The method used radioactive labels, which limited where it could be performed and eventually fell out of favor as enzyme-based and fluorescence-based labels proved safer and more practical. But the core insight, that an antibody could serve as a detection tool with exquisite sensitivity, unlocked the entire diagnostic category. Every ELISA kit, rapid test strip, and multiplex bead panel in use today traces its conceptual lineage back to that insulin assay.30PubMed. Development of the Insulin Radioimmunoassay, the Watershed Moment in Diabetes Research: Revisiting 1960 Diabetes Classics by Berson and Yalow